|
Novel Breast Cancer Therapies: Antibody-Drug Conjugates
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with an estimated 15% of cases being human epidermal growth factor receptor 2 (HER2)"positive and 12% being triple-negative (ACS, 2019). Antibody-drug conjugates have revolutionized the treatment of HER2-positive, triple-negative, and, most recently, HER2-low unresectable or metastatic breast cancer. These drugs combine a tumor antigen"targeted monoclonal antibody with a cytotoxic payload to permit the s... |
|
|
Novel Breast Cancer Therapies: Immune Checkpoint Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is
estimated that 12% of cases are classified as triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) (ACS, 2019). Immune checkpoint inhibition in combination with chemotherapy is a new strategy in breast cancer, with the first immunotherapy approval for patients with advanced triple-negative disease occurring in 2019. Immune checkpoint inhibit... |
|
|
Novel Breast Cancer Therapies: CDK4/6 Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, with 287,850 new cases and 43,250 deaths predicted to occur in 2022 (ACS, 2022). Making up 73% of cases, hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative disease is the most common subtype of breast cancer (ACS, 2019). Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are a novel therapeutic option for patients with HR-positive, HER2-negative advanced breast cancer. T... |
|
|
Novel Breast Cancer Therapies: HER2 Tyrosine Kinase Inhibitors
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are HER2-positive and may therefore benefit from human epidermal growth factor receptor 2 (HER2) inhibition (ACS, 2019). By blocking downstream oncogenic signaling in HER2-positive breast cancer cells, HER2 tyrosine kinase inhibitors improve outcomes for patients with HER2-positive breast cancer. These agents have advantages over monoclonal antibody HER2 inhibitors because the... |
|
|
Novel Breast Cancer Therapies: Monoclonal Antibodies
STATEMENT OF NEED
Breast cancer is the most common cancer diagnosed in women, and it is estimated that 15% of cases are human epidermal growth factor receptor 2 (HER2)"positive and may therefore benefit from HER2 inhibition (ACS, 2019). Monoclonal antibodies target HER2 function by preventing the formation or blocking the signaling of the oncogene HER2. The resulting loss of signaling downregulates oncogenic signaling in the cancer cell, resulting in improved clinical outcomes for pati... |
|
|
Novel Breast Cancer Therapies: PARP Inhibitors
STATEMENT OF NEED
Breast cancer is the most commonly diagnosed cancer in women. A BRCA1 or BRCA2 mutation is found in approximately 5% of patients with breast cancer and is detected in 30% of patients who have a family history of breast or ovarian cancer (ACS, 2019). In patients with human epidermal growth factor receptor 2 (HER2)"negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, inhibition of poly"(ADP-ribose) polymerase (PARP) is highly ef... |
|
|
Novel Breast Cancer Therapies: PI3K Inhibitors
STATEMENT OF NEED
Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)"positive/human epidermal growth factor receptor 2 (HER2)"negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers... |
|
|
Oncology Data Advisor™: Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma
STATEMENT OF NEED
Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians need to continually update their working knowledge of emerging data and consensus recommendations that can rationally inform clinical decision making. In Modul... |
|
|
Exploring New Treatment Advances for Acid Sphingomyelinase Deficiency in Adults
STATEMENT OF NEED
Acid sphingomyelinase deficiency (ASMD) is a rare, hereditary lysosomal storage disease with multisystemic manifestations, including splenomegaly, hepatomegaly, interstitial lung disease, dyslipidemia, bone marrow and lymph node involvement, and sometimes neurological and peripheral nerve involvement. While the most severe form of ASMD, infantile neurovisceral ASMD, results in death in early childhood, chronic forms of ASMD have more prolonged survival but are associated w... |
|
Navigating pain management, safe opioid prescribing, and opioid use disorder
This program is presented in six thirty minute sessions that can be completed individually.
The sessions are:
Session 1: Pain Taxonomy, pathogenesis, and assessment
Session 2: Developing a patient-centered pain treatment plan
Session 3: Non-opioid analgesics: Evidence and clinical pearls
Session 4: Opioid analgesics: From A to Z
Session 5: Clinical use of opioids: Safe prescribing and appropriate monitoring
Session 6: The exit strategy: When the treatment becomes the ... |
|
|
What Comes Next in the COVID-19 Pandemic?
2020 will be a year to remember. A century after the 1918 Influenza Pandemic, history has its eyes on us. Between ‘Warp Speed’ vaccinations, supplies shortages, and dynamic literature, this high-level review on COVID-19 provides an actionable approach to fighting this pandemic. |
|
|
Raising the Bar for Patient Outcomes With Immunotherapy in Early-Stage Resectable NSCLC
Target Audience
The target audience for this educational initiative is oncologists, oncology NPs, PAs, and nurses, pulmonologists, pulmonology NPs and PAs, pathologists, and pharmacists.
Program Overview
Are you up to date on the role of immunotherapy in the setting of non-small cell lung cancer (NSCLC)? In this educational activity, experts Heather Wakelee, MD, and Meghan Ramsey, MD, explore how to select patients with early-stage resectable NSCLC who may derive benefit from immunotherap... |
|
|
RH Treatment in the Real World: AHA 2022 Highlights
Target Audience
This activity has been designed to address the educational needs of primary care providers, including internists, family physicians, clinical pharmacists, nurse practitioners, and PAs, as well as nephrologists, cardiologists, endocrinologists, obesity specialists, gerontologists, and other clinicians who are involved or interested in the management of patients with resistant hypertension (RH).
Program Overview
Blood pressure control rates have been steadily declining in th... |
|
|
The Future of RH Treatment: AHA 2022 Highlights
Target Audience
This activity has been designed to address the educational needs of primary care providers, including internists, family physicians, clinical pharmacists, nurse practitioners, and PAs, as well as nephrologists, cardiologists, endocrinologists, obesity specialists, gerontologists, and other clinicians who are involved or interested in the management of patients with resistant hypertension (RH).
Program Overview
The American Heart Association 2022 Scientific Sessions was fer... |
|
|
Recent Advances in the Management of Patients with Advanced Hepatocellular Carcinoma: How Does Your Approach Compare with the Experts’?
Target Audience
This activity is intended for US-based hematologists/oncologists, hepatologists, gastroenterologists, interventional radiologists, pathologists, and other members of the multidisciplinary oncology team (NPs, PAs, pharmacists) responsible for the care of patients with HCC.
Program Overview
This case-based enduring virtual activity is designed to improve clinicians’ ability to use an evidence-based approach for the selection of therapies for the treatment of patients with ... |
|
|
Basic Compounding and Calculations Home Study
The overall goal of this 12-hour knowledge-based program is to provide the pharmacists and technicians with a review of the calculations they will need to make in order to prepare the variety of medications their patients may need to attain the greatest therapeutic actions from their medications with the fewest undesirable side effects.
Pharmacists and pharmacy technicians all compound medications at some level in their practice. A review of the major topics that will be included are the f... |
|
|
What Would You Do? An Interactive and Evidence-Based Educational Session on MS Treatment Approaches
Target Audience
This activity is designed to meet the educational needs of neurologists, advanced practice nurses, physician assistants, nurses, pharmacists, and other members of the healthcare professional team who care for people with MS.
Program Overview
An interactive, case-based activity designed to challenge learners' thinking and decision-making skills, while providing evidence and expert insights related to considerations in the care of people living with MS.
Learning Obje... |
|
|
Part 1: Understanding the Fundamentals of Pain
Target Audience
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
Program Overview
Pain is a pervasive problem in the United States that poses many challenges to clinicians and patients. The potential for opioid misuse, abuse, and addiction contributes to the complexity of appropriate pain management. This CME/CE activity, which is Part 1 of a three-part series ... |
|
|
Part 2: Best Practices for Prescribing Opioids in Primary Care
Target Audience
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
Program Overview
Pain continues to be a major public health problem in the United States, causing reductions in patients’ daily function and quality of life. Despite the benefits of opioid analgesics, untreated and undertreated acute and chronic pain persists. Thus, education on safe opioid pres... |
|
|
Part 3: Opioid Risk Evaluation, Mitigation, and Management
Target Audience
This activity is designed specifically for primary care clinicians, registered nurses, advanced practice registered nurses, pharmacists, and other members of the healthcare team.
Program Overview
The opioid epidemic is a national health crisis that results in tens of thousands of opioid-related overdose deaths annually. It is critical that the millions of patients with pain receive appropriate care while mitigating the risks of opioid misuse, abuse, and diversion. This CME... |
|
|
Generational Shift: Why We Should Modify our Instructional Strategies for the Next Generation of Pharmacists
Do you feel like your interactions with Millennial students differ from those of previous generations? This course enables pharmacist educators to understand the attitudes, work ethics, and preferred methods of communication of the Millennial generation as well as how they learn and study. Hear discussion on effective strategies based on generational research and advances in neuroscience to implement in the classroom and experiential setting that will aid you in working with and teaching the ... |
|
|
Refining Management of Classical Hodgkin Lymphoma: What’s on the Horizon for Pediatric Management and AYA Survivorship
Target Audience
The educational design of this activity addresses the needs of community-based and academic/specialist hematologists, hematologic oncologists, medical oncologists, hematopathologists, primary care providers, family practitioner internists, hematology/oncology nurses and nurse navigators, nurse practitioners, physician assistants, and pharmacists.
Program Overview
New treatments are poised to expand the armamentarium for pediatric classical Hodgkin lymphoma (cHL). Given the... |
|
|
Community Practice Connections™: Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management
Target Audience
This educational activity is directed toward Cardiologists, Internists, Primary Care Physicians, Endocrinologists, Nephrologists, Hospitalists, Physician Assistants, Nurse Practitioners, Pharmacists, Certified Diabetes Educators.
Program Overview
Heart failure (HF) remains a leading cause of morbidity and mortality. Despite the fact that guideline-directed medical therapy (GDMT) has been shown to improve HF survival, GDMT optimization in clinical practice remains poor. Rec... |
|
|
Dermatological Compounding with Pain Management
Class Dates & Registration
TBD: email training@acainfo.org to be put on the notification list.
DERMATOLOGICAL COMPOUNDING WITH PAIN MANAGEMENT is an accredited 15 hour (1.5 CEUs) practice-based course designed for pharmacists, technicians, marketers, and students who want to learn more about a growing segment for compounding. Physicians and other healthcare professionals are welcome to attend. This course is a combination of didactic lectures for content and laboratory activities to en... |
|
|
Dermatological Compounding Home Study
This is a 5-hour knowledge-based home study learning program, designed for compounding pharmacists and technicians that will cover the definition and discussion of creams, emulsions, ointments, pastes, gels, PLOs, solutions, lotions, powders, and bases (semi-solid and commercially available).
This module also covers compendial requirements (microbial content, minimum fill, quality control, preparation and labeling, patient counseling, and consultations) and establishing and extending beyon... |
|
|
What's Your Big Idea? (Pharmacist)
2020 is in the past, and 2021 is here. Start the year off right with innovating pharmacy practice. Learn how to think outside the box, generate ideas, and transform practice. This interactive session will review the latest literature and research in change management and innovation to help you make the next great idea. |
|
|
FERPA: A Guide for Preceptors
This course provides a general overview of the Family Educational Rights and Privacy Act which protects student privacy as it relates to their educational records. It also provides guidance for pharmacist preceptors to comply as part of the educational team. |
|
|
Challenging Invasive Fungal Infections: Current and Emerging Pharmacologic Strategies
Target Audience
Primary audience: This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists/clinical microbiologists, hematologists/oncologists, pharmacists, pediatric infectious disease specialists, transplant specialists, and other healthcare providers responsible for the management of invasive fungal infections.
Secondary audience: Primary care providers, GI, dermatology, and rheumatology specialists who work in the endemi... |
|
|
Best Practice™: Streamlining the Pathway to Successful Implementation of Gene Therapy in Hemophilia B " A Focus on the Hub and Spoke Model
Target Audience
This educational activity is directed toward hematologists, specialty nurse practitioners/physician assistants, pharmacists, and nurses who manage patients with hemophilia B.
Program Overview
In this online, on-demand webcast, a renowned expert in the management of patients with hemophilia B will discuss the development of gene therapy for treating this disorder. In this educational program, this expert discusses the latest data regarding clinical trials of various gene th... |
|
|
Identifying Patients at High Risk of COVID-19 Complications: Considerations for Community Care to Reduce Morbidity, Mortality, and Hospitalization Risk
Target Audience
This activity is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations.
Program Overview
This program uses a game-based approach to explore the current understanding of COVID risk assessment, diag... |
|
|
All Abuzz About CLL: Exploring Fixed-Duration Regimens and Cardiotoxicity Management
Target Audience
The target audiences for the proposed HCP activity are community neurologists, neuromuscular specialists, immunologists, PCPs, hospitalists, emergency physicians, APNs, RNs, pharmacists.
Program Overview
Differentiating chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) from other immune-mediated inflammatory neuropathies can be challenging for clinicians. Misdiagnoses are common and can lead to poor outcomes for patients. However, newly revised guidelines fo... |
|
|
Collaborating Across the Continuum™: Taking IgA Nephropathy Management to the Next Level
Target Audience
This activity is intended for nephrologists, primary care providers, specialty pharmacists, managed care professionals, nurse practitioners, physician assistants, registered nurses, and other members of the IgAN care team.
Activity Overview
Immunoglobulin (Ig) A nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide, and it is considered a significant cause of end-stage renal disease (ESRD) in young adults. The precise pathogenesis of IgAN remai... |
|
|
It's Time to be Thriving: Starting with the Whole You
Many pharmacists are facing professional burnout due to increasing workload in practice and demands in their role as preceptors. Practicing pharmacists find themselves withstanding ‘casual pharmacy practice’ with a survival mode mentality and feeling dissatisfied.
The goal of this session is to move preceptors from a survival mentality to experiencing a thriving pharmacy career through promoting a culture of well-being in precepting. Attendees in the session will create a plan to priorit... |
|
|
What's New in Type 2: The 2021 Diabetes Update (Pharmacist)
Evidence-based guidelines and recommendations for the prevention, early detection, and treatment of diabetes are critical to optimal health and outcomes for people with diabetes. It is well known that monotherapy cannot achieve glycemic control for many people. When initiating a second-line therapy, clinicians must select among several treatment options and look beyond glycemic lowering. This interactive session will discuss the evidence and best practices of care for people with diabetes, inc... |
|
|
Ace the Case: Multiple Myeloma Presentation in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: Treating First Multiple Myeloma Relapse in the Community Setting
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Ace the Case: R/R MM After 4 Lines of Therapy: What are the options?
Effective treatment of multiple myeloma (MM) requires significant clinical coordination, as MM treatment plans are highly individualized. Treatment is influenced by many factors, including patient demographics, biomarkers, level of disease progression, response to previous treatments, individual treatment goals, and the preferred treatment paradigms of individual practitioners.
This educational program is designed to meet the educational needs of the members of the care team (oncologists, h... |
|
|
Catching Zzzs: The Role of Dual Orexin Receptor Antagonists for Insomnia / 2222
Target Audience
This activity has been designed to meet the educational needs of physicians, nurse practitioners, physician assistants, and pharmacists practicing in primary care, neurology, and psychiatry.
Program Overview
Insomnia is responsible for a wide range of short-term and long-term impairments and negative health outcomes. Differences in mechanisms among insomnia therapies have important implications for their use in specific patients and among specific patient populations. Dual... |
|
|
Are We Nearing the End of the Debate Regarding Steroid Efficacy and Safety in IgAN?
Target Audience
The educational design of this activity addresses the needs of nephrologists, internists, PCPs, dialysis staff and medical directors, pharmacists, and aligned HCPs.
Statement of Need/Program Overview
If left untreated, immunoglobulin‐A nephropathy (IgAN) can lead to kidney failure, dialysis, and transplantation. The current standard of care, RAS inhibition, has limited efficacy, while recently updated KDIGO guidelines for the management of IgAN highlight the risks associ... |
|
|
WEBINAR: Long Walk Out of the Woods: A Physician's Story of Addiction, Depression, Hope, and Recovery
Share my story of addiction recovery to normalize seeking help while working in the medical profession. To distinguish mental health and addiction. Discuss the barriers and obstacles in the way. How can we all advocate for change?
This session was initially presented at the 2022 ACA | ACVP | PPHI Annual Conference & Expo held on February 23-26, 2022. |
|
|
WEBINAR: Diversity and Inclusivity: "Must Haves" For Pharmacy
Pharmacy professionals seek to provide high-quality health care that leads to optimal health outcomes in all patient populations. However, these desired outcomes and levels of health equity have not yet been achieved due to the lack of diversity and inclusivity in health professions and pharmacy education and practice, and the compounding effect of health disparities. The good news is we can change this scenario with more awareness and commitment to implementing strategies that foster must hav... |
|
|
WEBINAR BUNDLE: ACA | ACVP | PPHI Annual Conference & Expo - Veterinary Pharmacy Bundle
Earn up to 3 hours of continuing education focused on community veterinary pharmacy when you purchase the 2021 ACA | ACVP | PPHI Annual Conference & Expo Veterinary Pharmacy Bundle, originally presented February 26, 2021.
Exotic Pets and Your Imagination, Randy Carr, RPh, FAPC, FACVP
At the conclusion of this program, the participating pharmacist or pharmacy technician will be able to:
• Discuss the difficulties of treating different animals
• Outline a plan to treat differe... |
|
|
WEBINAR BUNDLE: Veterinary Pharmacy for Exotic Animals Bundle
Earn up to 3 hours of continuing education focused on Veterinary Pharmacy when you purchase the Veterinary Pharmacy for Exotic Animals Bundle, originally presented at the Annual Conference & Expo and the Veterinary Pharmacy Conference.
1. "Data Gaps in Aquatic Pharmacology: Identifying Challenges and Needs", Jamie Torres, DVM
2. "Exotic Pets and Your Imagination", Randy Carr, RPh, FAPC, FACVP
3. "You Need to Treat What? Meeting the Unique Pharmacy ... |
|
|
WEBINAR: Safeguard Your Compounding Pharmacy: Quality Control Tests for Dosage Forms and Common Pitfalls
It is important for compounding pharmacy and outsourcing facility testing programs to align with USP and FDA requirements for sterile and non-sterile dosage forms. Some of the same difficulties pharmacists and technicians face in creating a drug formulation also relate to getting accurate and representative results from quality control testing. Attendees will discover common pitfalls and uncover the scientific and technical challenges in testing.
This session was originally presented at th... |
|
|
WEBINAR BUNDLE: ACA New Member Bundle
The ACA New Member Bundle is accredited for 3.0 contact hours (0.3 CEUs) of continuing education credit for pharmacists and pharmacy technicians. Shortly after joining ACA, new members should receive a “Welcome Email” with a code to receive the ACA New Member Bundle at no cost*. Current members and non-members can purchase the bundle by clicking below.
Webinar 1: Opportunities in Wellness: Integrating Advanced Point of Sale Functional Testing in Community Pharmacy - Hillary Howell,... |
|
|
WEBINAR: Exotic Pets and Your Imagination
This webinar will discuss the problems of treating exotic pets and zoo animals--what questions to ask, who to talk to, and what resources you can use for answers.
The American College of Apothecaries (ACA) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACA has accredited this program for 1.0 contact hour (0.1 CEUs) of continuing education credit for pharmacists and pharmacy technicians. |
|
|
WEBINAR BUNDLE: Veterinary Pharmacotherapy Basics Bundle
The Veterinary Pharmacotherapy Basics Bundle is accredited for 2.0 contact hours (0.2 CEUs) of continuing education credit for pharmacists and pharmacy technicians. Shortly after joining ACVP, new members will receive a “Welcome Email” with a code to receive the Veterinary Pharmacotherapy Basics Bundle at no cost*. Current members and non-members can purchase the bundle by clicking below.
Webinar 1: Not So Tiny Humans: Understanding Anatomy & Physiology of Dogs and Cats
Pharma... |
|
|
WEBINAR: Policy and Payment for Pharmacists Maternal Health Services
Research shows that pharmacists add significant value to the healthcare system. That value is, as of yet, largely unrealized in maternal health services. To decrease infant and maternal mortality, preterm birth, and unintended pregnancies, states should look to pharmacists as a capable workforce, ready to implement solutions. Allowing pharmacists to provide primary care services to pregnant women and those capable of pregnancy will positively impact public health.
The American College of Ap... |
|
|
WEBINAR: Not So Tiny Humans - Understanding Anatomy & Physiology of Dogs and Cats
Pharmacists and pharmacy technicians dispensing and compounding medications for non-human patients will benefit from learning the pharmacokinetic and metabolic differences in dogs and cats. The presentation will address the anatomical and physiological differences in dogs and cats compared to humans. These differences impact drug bioavailability, metabolism, and elimination. This knowledge will enhance patient care pharmacists provide for non-human patients.
The American College of Apotheca... |
|
|
WEBINAR: Disaster Preparedness
This program will present practical considerations for pharmacists to prepare their pharmacies for disasters and future public health emergencies. The concepts presented will assist pharmacists in ensuring continuity of operations in disaster circumstances so as to provide ongoing access by patients to medicines and pharmacist services. Further, pharmacists will learn about how to integrate effectively into local public health response activities.
The American College of Apothecaries (ACA) ... |
|